Value Investing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Wallace Rivers who wrote (63129)	1/9/2020 11:03:45 PM
From: T-Mac	of 78717

RE: WBA I like this one a lot and have been adding the last couple of days. FWIW, when I was working for this company the gross profit per prescription filled was north of $12. It seems like this number is sliding closer to $11/script these days but that does not worry me. They have continued to grow their market share and should their prescription business continue to be pressured downwards, this will only further increase their market share as lower volume competitors will be forced out. An aging population is a major tailwind here as well I'm also optimistic that they can squeeze more out of the front end of their stores. They have started bringing LabCorp into many stores and have been working on getting Boots' popular cosmetic line into even more stores. Additional strategies of bringing low-cost groceries into their stores through Kroger and revamping their technology with Microsoft could also bring improvements. Keep in mind they also own more than a quarter of drug distributor AmerisourceBergen. The company's CEO also owns a significant amount of the stock. All things considered, this company is certainly undervalued IMO.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next